MediWound Ltd.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $13.68
- 52-Week Range
- $11.80 – $19.70
- Market Cap
- $195.85M
- P/E (TTM)
- —
- EPS (TTM)
- -2.57
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 5.55
- PEG Ratio
- —
- Return on Equity
- -57.39%
- Return on Assets
- -26.41%
- Gross Margin
- 19.54%
- Operating Margin
- -337.63%
- Profit Margin
- -234.98%
- Current Ratio
- 2.23
- Debt/Equity
- 0.26
- Total Debt
- $8.30M
- Free Cash Flow
- $-30.72M
- Revenue Growth
- -34.20%
- Earnings Growth
- —
- Enterprise Value
- $156.95M
Market Snapshot
About
MediWound Ltd. is an Israeli biopharmaceutical company specializing in the development, manufacturing, and commercialization of enzymatic therapeutics for severe burns, chronic wounds, and other hard-to-heal wounds. The company markets NexoBrid for burn wound debridement and EscharEx for chronic wound treatment.